CJC Open · Jul 20, 2026
Glucagon-Like Peptide-1 Receptor Agonists and Outcomes in Transthyretin Amyloid Cardiomyopathy with Type 2 Diabetes Mellitus
By Jain H, Soni K, Patel N et al.
Transthyretin amyloid cardiomyopathy (ATTR-CM) leads to heart failure (HF), with limited therapies available. Data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in ATTR-CM and type-2 diabetes mellitus (T2DM) remain scarce. Using the TriNetX Global Collaborative Research Network (2005-2025), we identified adults with ATTR-CM and concomitant T2DM and stratified them by GLP-1 RA use, and performed 1:1 propensity-score matching. A total of 1269 matched pairs were analyzed. At 1 year, GLP-1 RA use was associated with lower all-cause mortality, HF events, myocardial infarction, stroke, major adverse cardiac and cerebrovascular events, arrhythmias, and rehospitalization. GLP-1 RA use may improve outcomes in ATTR-CM patients with T2DM.
doi.org/10.1016/j.cjco.2026.07.008Open accessPubMed 43042232Interventions